TY - JOUR
T1 - The current status and unmet needs in the management of psoriatic arthritis
T2 - Viewpoint from physicians in Taiwan
AU - Li, Tzu Hao
AU - Liao, Hsien Tzung
AU - Huang, Yi Fan
AU - Shen, Yu Chuan
AU - Chiu, Yao Chang
AU - Chen, Wei Sheng
AU - Chen, Ming Han
AU - Tsai, Chang Youh
AU - Chang, Deh Ming
PY - 2017/2/4
Y1 - 2017/2/4
N2 - Background/Purpose: To analyze the real-world clinical practice for the treatment of psoriatic arthritis (PsA) and to assess physicians' prescription, difficulties in diagnosis, therapeutic strategy, rationales for biologic therapies and unmet needs in Taiwan. Methods: We conducted a nationwide cross-sectional observational study by face-to-face in depth interviews with 50 rheumatologists and 30 dermatologists who took care of patients with PsA. Results: The major procedures for recognizing PsA included joint, skin and nail examinations, radiographic imaging, and medical history. More dermatologists established the diagnosis when psoriatic patients with arthritis didn't present with rheumatoid factors (p < 0.05). For milder arthritis, physicians tended to prescribe etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs). The efficacy, safety, retention rate, and non-parenteral administration are the major concerns of physicians which are also the primary unmet needs in the current management of PsA. Conclusion: This survey showed the status quo in Taiwan of the clinical management for PsA including diagnostic difficulties, therapeutic consideration, rationales for biologic DMARDs selection and unmet needs in treatment. It has indicated that interdisciplinary collaboration may further improve the quality for PsA care. These results may help establish new strategy to develop next generation biologics.
AB - Background/Purpose: To analyze the real-world clinical practice for the treatment of psoriatic arthritis (PsA) and to assess physicians' prescription, difficulties in diagnosis, therapeutic strategy, rationales for biologic therapies and unmet needs in Taiwan. Methods: We conducted a nationwide cross-sectional observational study by face-to-face in depth interviews with 50 rheumatologists and 30 dermatologists who took care of patients with PsA. Results: The major procedures for recognizing PsA included joint, skin and nail examinations, radiographic imaging, and medical history. More dermatologists established the diagnosis when psoriatic patients with arthritis didn't present with rheumatoid factors (p < 0.05). For milder arthritis, physicians tended to prescribe etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs). The efficacy, safety, retention rate, and non-parenteral administration are the major concerns of physicians which are also the primary unmet needs in the current management of PsA. Conclusion: This survey showed the status quo in Taiwan of the clinical management for PsA including diagnostic difficulties, therapeutic consideration, rationales for biologic DMARDs selection and unmet needs in treatment. It has indicated that interdisciplinary collaboration may further improve the quality for PsA care. These results may help establish new strategy to develop next generation biologics.
KW - Anti-tumor necrosis factor
KW - Biologic DMARDs
KW - Multidisciplinary team-care
KW - Psoriatic arthritis
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85019959236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019959236&partnerID=8YFLogxK
U2 - 10.1016/j.jfma.2017.05.001
DO - 10.1016/j.jfma.2017.05.001
M3 - Article
AN - SCOPUS:85019959236
SN - 0929-6646
JO - Journal of the Formosan Medical Association
JF - Journal of the Formosan Medical Association
ER -